About products

Cornea is the outermost part of the human eye. After the onset of the disease, the cornea is usually not self-healing. When the cornea is due to trauma, acid-base burns, keratitis, scar or inflammation and other reasons, it causes varying degrees of haze and necrosis of the cornea. In this way, the light is blocked when passing through the cornea, which affects the vision of patients to varying degrees. At this time, it is necessary to replace the patient's turbid cornea in order to restore vision. It is usually necessary to obtain a cornea donated by another person for transplantation. This procedure is called keratoplasty.

Micof was developed and designed in the 1990s, and was applied to human body in 2000. In the past 20 years, hundreds of blind patients have been successfully treated, and these patients have been able to recover their vision after surgery.


A detailed introduction of Micof

Optical column, peripheral support


The optical part made of transparent material with excellent optical properties and stable physical and chemical properties is used to replace the turbid cornea which obstructs the optical path of the eyeball;


After years of research and test, all the materials are independently developed and manufactured by the company, with independent intellectual property rights. The materials are processed by special processes,Good transparency, elasticity, high durability, easy operationIt has higher biological safety and can interact with surrounding tissues Rapid healing


MiOk combines a novel and relatively simple procedure,It provides an effective, therapeutic and affordable treatment for millions of people with corneal related visual impairment, far superior to any available alternative.

Compared with other kpro

There is no need to use donor cornea during implantation, which can reduce the occurrence of complications and rejection. MiOk artificial cornea implantation requires a simple two-stage operation, and the operation is basically completed under the condition of closed eyeball, which can effectively reduce the occurrence of intraocular infection.

There is no need for the intervention of living cornea

There is no need for the intervention of living cornea. MiOk artificial cornea implantation does not need the intervention of living cornea, but only needs to implant the product itself into the cornea, which greatly saves the use of biological cornea (donor).

Two stage operation
Phase I

The corneal lamellae of the patients were separated and the stent was implanted. After the stent implantation, the conjunctiva was covered and fixed. After the operation, the patients were treated with anti-inflammatory and hormone drugs, and the growth was restored for 3 months. The operation is not in the eye.

Phase II

Surgery was performed on eyes with stents installed. First, the central part of the stent was excised with a trephine, then the lens was excised and the anterior vitrectomy was performed. During the operation, only a 2mm hole distance should be opened, and the doctor will install the lens column quickly to avoid the occurrence of intraocular infection.

Gatifloxacin eye ointment and anti-inflammatory drug infusion were used after operation. They are usually discharged after 3 days. As a part of the implantable surgery, mikh designed a special artificial cornea surgical instrument, which shortened the complex process of surgery and turned the complex surgery into a systematic and accurate implantable process. This process is easy to teach and can be learned in a few days.

This procedure minimizes the exposure time of the contents of the eye, which is known as "open eye", greatly reducing the associated risks. The patent design of Micof implantation is the result of extensive, multidisciplinary (physical, chemical, biological) research and development process.

Micof and its large aperture PMMA column provide unprecedented visual performance and broad field of vision. The back side of the MiOk column can be easily fixed in the central hole area to maintain the integrity of the eye. This novel biological suture integration method further ensures the safety of the device through its optical components, thus ensuring reliable and rapid healing and long-term retention. Because it is 100% synthetic, sterile and composed of inert materials, the device will not carry infectious substances or cause excessive inflammation. This will improve the quality of life and provide more effective patient care.

Comparison between Micof and traditional cornea
MHz artificial cornea Micof
Many problems of traditional corneal transplantation
1.Combining technology with innovation

By integrating synthetic materials with human tissues, Micof combines novel biological integration technology with innovative ideas to create a breakthrough solution to meet the unmet needs of Ophthalmology. (innovation)

2.It is stable

The material has enough stability, no chemical and physical changes, no degradation, no cracking, no dissolution, and the material can be used for a long time.

3.Good optical properties
4.It can coexist with autologous corneal tissue for a long time.
5.Fundus protection
6.It is not limited by the donor cornea and does not need to be implanted together.
1.Lack of donor cornea

At present, most of the corneal materials in the world are from fresh cadavers (donors). It is better to keep the corneal epithelium intact, the stroma transparent and the thickness unchanged (no edema) no more than 12 hours after death. If the fresh corneal materials are treated with preservation solution or deep hypothermia, they can be kept for several days or weeks.

2.Survival rate

However, whether corneal transplantation can survive and remain transparent without rejection depends on a variety of reasons. The compatible antibody between allogeneic tissues plays an important role. According to the latest academic research, 5 to 7 of 10 patients with corneal transplantation have the phenomenon of rejection, which eventually leads to several times of transplantation failure and permanent blindness

3.The blank of traditional corneal transplantation indications

Traditional corneal transplantation is only suitable for patients with mild corneal injury, but it is ineffective for patients with acid-base, chemical, engineering and external injury. According to the data given by the China Disabled Persons' Federation, there are about 3 million to 4 million corneal blindness patients in China. (from 2006 to the end of 2008, the number of keratoplasty patients in China was 5000, compared with 3500 in 2009.)


For example: herpetic keratitis | corneal degeneration | ICE syndrome | aniridia | SJS | OCP | alkali burn | vascularized corneal indications Acid, alkali, burn, explosive injury, multiple corneal transplantation failure, severe corneal injury patients, high-risk corneal transplantation failure, immune disease Stevens Johnson syndrome and other patients with poor prognosis and blindness, corneal injury caused by various reasons.